4:30 pm Gilead Announces Results From Phase 3 Study of Sofosbuvir Among Hepatitis C Patients in Japan; The study met its primary efficacy endpoint
View todays social media effects on GILD
View the latest stocks trending across Twitter. Click to view dashboard
See who Gilead is hiring next, click here to view
